CSPG4 and neoplasm: As expected, we did not detect binding to IGROV1 ovarian or SKBR3 breast cancer cells (neither express CSPG4, but overexpress tumor antigens FRα and human epidermal growth factor receptor 2 (Her2), respectively, confirmed by binding of target antigen-specific IgEs) (Fig. 2c).